However, development was discontinued in 2007 after the largest Phase IIb trial failed to demonstrate statistically significant weight loss compared to placebo
administered BPC 157 (10mcg/kg or 10 ng/kg) orally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery to test its effects on short bowel syndrome in rats, observing the effectiveness of both forms of administration [24]
However, following a balanced, nutrient-dense meal plan can improve results and make the body more responsive to metabolic interventions
Doping control analysis of TB-500, a synthetic version of an active region of thymosin 4, in equine urine and plasma by liquid chromatographymass spectrometry
Evaluate Canadian options alongside international sources, considering total cost including shipping and any applicable duties